56 research outputs found
Effectiveness of the female condom in preventing HIV and sexually transmitted infections: a systematic review and meta-analysis
Abstract
Background
The effectiveness of female condoms for preventing HIV and sexually transmitted infections (STIs) remains inconclusive. We examined the effects of female condoms on the acquisition of HIV and STIs.
Methods
We searched four databases, two trial registries, and reference lists of relevant publications in October 2018 and updated our search in February 2020. We screened search output, evaluated study eligibility, and extracted data in duplicate; resolving differences through discussion. We calculated the effective sample size of cluster randomised trials using an intra-cluster correlation coefficient of 0·03. Data from similar studies were combined in a meta-analysis. We performed a non-inferiority analysis of new condoms relative to marketed ones using a non-inferiority margin of 3%. We assessed the certainty of evidence using GRADE.
Results
We included fifteen studies of 6921 women. We found that polyurethane female condoms (FC1) plus male condoms may be as effective as male condoms only in reducing HIV acquisition (1 trial, n = 149 women, RR 0.07, 95%CI 0.00–1.38; low-certainty evidence). However, the use of FC1 plus male condoms is superior to male condoms alone in reducing the acquisition of gonorrhoea (2 trials, n = 790, RR 0.59, 95%CI 0.41–0.86; high-certainty evidence) and chlamydia (2 trials, n = 790, RR 0.67, 95%CI 0.47–0.94; high-certainty evidence). Adverse events and failure rates of FC1 were very low and decreased during follow up. Although the functionality of newer female condoms (Woman’s, Cupid, Pheonurse, Velvet, and Reddy) may be non-inferior to FC2, there were no available studies assessing their efficacy in preventing HIV and STIs.
Conclusion
The use of female plus male condoms is more effective than use of male condoms only in preventing STIs and may be as effective as the male condom only in preventing HIV. There is a need for well conducted studies assessing the effects of newer female condoms on HIV and STIs.
PROSPERO registration number
CRD4201809071
Contextualised strategies to increase childhood and adolescent vaccination coverage in South Africa : a mixed-methods study
CITATION: Wiysonge, Charles Shey et al. 2020. Contextualised strategies to increase childhood and adolescent vaccination coverage in South Africa : a mixed-methods study. BMJ Open, 10 (6):e028476, doi:10.1136/bmjopen-2018-028476.The original publication is available at: https://bmjopen.bmj.comIntroduction Despite the unparalleled success of immunisation in the control of vaccine preventable diseases, immunisation coverage in South Africa remains suboptimal. While many evidence-based interventions have successfully improved vaccination coverage in other countries, they are not necessarily appropriate to the immunisation needs, barriers and facilitators of South Africa. The aim of this research is to investigate barriers and facilitators to optimal vaccination uptake, and develop contextualised strategies and implementation plans to increase childhood and adolescent vaccination coverage in South Africa.
Methods The study will employ a mixed-methods research design. It will be conducted over three iterative phases and use the Adopt, Contextualise or Adapt (ACA) model as an overarching conceptual framework. Phase 1 will identify, and develop a sampling frame of, immunisation stakeholders involved in the design, planning and implementation of childhood and human papillomavirus immunisation programmes in South Africa. Phase 2 will identify the main barriers and facilitators to, and solutions for, increasing vaccination coverage. This phase will comprise exploratory qualitative research with stakeholders and a review of existing systematic reviews on interventions for improving vaccination coverage. Using the findings from Phase 2 and the ACA model, Phase 3 will develop a set of proposed interventions and implementation action plans for improving immunisation coverage in South Africa. These plans will be discussed, revised and finalised through a series of participatory stakeholder workshops and an online questionnaire, conducted as part of Phase 3.Publisher's versio
HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa
OBJECTIVES : Urban and rural HIV treatment programmes face different challenges in the long-term management of patients. There are few studies comparing drug resistance profiles in patients accessing treatment through these programmes. METHODS : HIV drug resistance data and associated treatment and monitoring information from adult patients failing first-line therapy in an urban and rural programme were collected. Data were curated and managed in SATuRN RegaDB before statistical analysis using Microsoft Excel 2013 and Stata Ver14 where clinical parameters, resistance profiles and predicted treatment responses were compared. RESULTS : Data from 595 patients were analyzed: 492 rural and 103 urban. The urban group had lower CD4 counts at treatment initiation (98 versus 126 cells/μl, p=0.05), had more viral loads done per year (median 3 versus 1.4, p< 0.01) and was more likely to have no drug resistance mutations detected (35.9% versus 11.2%, p<0.01). Patients in the rural group were more likely to have been on first-line treatment for a longer period, failed for longer, and have thymidine analogue mutations. Notwithstanding these differences, both groups had a comparable predicted response to standard second-line regimen, based on the genotypic susceptibility score. Mutations accumulated in a sigmoidal fashion over failure duration. CONCLUSIONS : The frequency and patterns of drug resistance, as well the intensity of virological monitoring, in adults with first-line therapy failure differed between the urban and rural site. Despite these differences, based on the genotypic susceptibility scores, the majority
of patients across both sites would be expected to respond well to the standard second-line regimen.This work was supported by the European Union (SANTE 2007 147–
790). The Hlabisa HIV Treatment and Care Programme has received support through the
United States Agency for International Development (USAID) and the President’s
Emergency Plan (PEPFAR) under the terms of Award No. 674-A-00-08-00001-00. Data
analysis and curation were also supported by a Flagship grant from the Medical Research
Council (MRC) of the Republic of South Africa (MRC- RFA-UFSP-01-2013/UKZN
HIVEPI).http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1468-12932018-02-27hb2017Immunolog
CD14+ macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide
BACKGROUND : Intestinal macrophages are key regulators of inflammatory responses to the gut microbiome and play
a central role in maintaining tissue homeostasis and epithelial integrity. However, little is known about the role of
these cells in HIV infection, a disease fuelled by intestinal inflammation, a loss of epithelial barrier function and
increased microbial translocation (MT).
METHODS : Phenotypic and functional characterization of intestinal macrophages was performed for 23 African AIDS
patients with chronic diarrhea and/or weight loss and 11 HIV-negative Africans with and without inflammatory
bowel disease (IBD). AIDS patients were treated with cotrimoxazole for the prevention of opportunistic infections
(OIs). Macrophage phenotype was assessed by flow cytometry and immuno-histochemistry (IHC); production of
proinflammatory mediators by IHC and Qiagen PCR Arrays; in vitro secretion of cytokines by the Bio-Plex Suspension
Array System. Statistical analyses were performed using Spearman’s correlation and Wilcoxon matched-pair tests.
Results between groups were analyzed using the Kruskal-Wallis with Dunn’s post-test and the Mann–Whitney U tests.
RESULTS : None of the study participants had evidence of enteric co-infections as assessed by stool analysis and
histology. Compared to healthy HIV-negative controls, the colon of AIDS patients was highly inflamed with increased
infiltration of inflammatory cells and increased mRNA expression of proinflammatory cytokine (tumour necrosis factor
(TNF)-α, interleukin (IL)-1β, IFN-γ, and IL-18), chemokines (chemokine (C-C motif) ligand (CCL)2 and chemokine (C-X-C)
motif ligand (CXCL)10) and transcription factors (TNF receptor-associated factor (TRAF)6 and T-box (TXB)21). IHC
revealed significant co-localization of TNF-α and IL-1β with CD68+ cells. As in IBD, HIV was associated with a marked
increase in macrophages expressing innate response receptors including CD14, the co-receptor for lipopolysaccharide
(LPS). The frequency of CD14+ macrophages correlated positively with plasma LPS, a marker of MT. Total unfractionated
mucosal mononuclear cells (MMC) isolated from the colon of AIDS patients, but not MMC depleted of CD14+ cells, secreted increased levels of proinflammatory cytokines ex vivo in response to LPS
CONCLUSIONS : Intestinal macrophages, in the absence of overt OIs, play an important role in driving persistentinflammation in HIV patients with late-stage disease and diarrhea. These results suggest intensified treatmentstrategies that target inflammatory processes in intestinal macrophages may be highly beneficial in restoringthe epithelial barrier and limiting MT in HIV-infected patients.This research and selected researchers (EC, TR, PM, SM and CS) were funded
in part by a grant from the Delegation of the European Union to South
Africa: “Drug Resistance Surveillance and Treatment Monitoring Network for
the Public Sector HIV Antiretroviral Treatment Programme in the Free State –
Sante 2007/147-790” and by a grant from the National Research Council of
South Africa, Unlocking the Future 61509.http://www.biomedcentral.com/bmcinfectdisam201
COVID-19 Is a multi-organ aggressor : epigenetic and clinical marks
The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both
genetic and environmental factors. Several viruses hijack the host genome machinery for
their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2
infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven
mechanisms, including DNA methylation and histone/chromatin alterations. These
epigenetic phenomena may respond to enhanced viral replication and mediate persistent
long-term infection and clinical phenotypes associated with severe COVID-19 cases and
fatalities. Understanding the epigenetic events involved, and their clinical significance, may
provide novel insights valuable for the therapeutic control and management of the COVID-
19 pandemic. This review highlights different epigenetic marks potentially associated with
COVID-19 development, clinical manifestation, and progression.http://www.frontiersin.org/Immunologyam2022Nuclear Medicin
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019
Background Accurate and up-to-date assessment of demographic metrics is crucial for understanding a wide range of
social, economic, and public health issues that affect populations worldwide. The Global Burden of Diseases, Injuries,
and Risk Factors Study (GBD) 2019 produced updated and comprehensive demographic assessments of the key
indicators of fertility, mortality, migration, and population for 204 countries and territories and selected subnational
locations from 1950 to 2019.
Methods 8078 country-years of vital registration and sample registration data, 938 surveys, 349 censuses, and 238 other
sources were identified and used to estimate age-specific fertility. Spatiotemporal Gaussian process regression (ST-GPR)
was used to generate age-specific fertility rates for 5-year age groups between ages 15 and 49 years. With extensions to
age groups 10–14 and 50–54 years, the total fertility rate (TFR) was then aggregated using the estimated age-specific
fertility between ages 10 and 54 years. 7417 sources were used for under-5 mortality estimation and 7355 for adult
mortality. ST-GPR was used to synthesise data sources after correction for known biases. Adult mortality was measured
as the probability of death between ages 15 and 60 years based on vital registration, sample registration, and sibling
histories, and was also estimated using ST-GPR. HIV-free life tables were then estimated using estimates of under-5
and adult mortality rates using a relational model life table system created for GBD, which closely tracks observed agespecific mortality rates from complete vital registration when available. Independent estimates of HIV-specific mortality
generated by an epidemiological analysis of HIV prevalence surveys and antenatal clinic serosurveillance and other
sources were incorporated into the estimates in countries with large epidemics. Annual and single-year age estimates of
net migration and population for each country and territory were generated using a Bayesian hierarchical cohort
component model that analysed estimated age-specific fertility and mortality rates along with 1250 censuses and
747 population registry years. We classified location-years into seven categories on the basis of the natural rate of
increase in population (calculated by subtracting the crude death rate from the crude birth rate) and the net migration
rate. We computed healthy life expectancy (HALE) using years lived with disability (YLDs) per capita, life tables, and
standard demographic methods. Uncertainty was propagated throughout the demographic estimation process,
including fertility, mortality, and population, with 1000 draw-level estimates produced for each metric.
Findings The global TFR decreased from 2·72 (95% uncertainty interval [UI] 2·66–2·79) in 2000 to 2·31 (2·17–2·46) in
2019. Global annual livebirths increased from 134·5 million (131·5–137·8) in 2000 to a peak of 139·6 million
(133·0–146·9) in 2016. Global livebirths then declined to 135·3 million (127·2–144·1) in 2019. Of the 204 countries and
territories included in this study, in 2019, 102 had a TFR lower than 2·1, which is considered a good approximation of
replacement-level fertility. All countries in sub-Saharan Africa had TFRs above replacement level in 2019 and accounted
for 27·1% (95% UI 26·4–27·8) of global livebirths. Global life expectancy at birth increased from 67·2 years (95% UI
66·8–67·6) in 2000 to 73·5 years (72·8–74·3) in 2019. The total number of deaths increased from 50·7 million
(49·5–51·9) in 2000 to 56·5 million (53·7–59·2) in 2019. Under-5 deaths declined from 9·6 million (9·1–10·3) in 2000
to 5·0 million (4·3–6·0) in 2019. Global population increased by 25·7%, from 6·2 billion (6·0–6·3) in 2000 to
7·7 billion (7·5–8·0) in 2019. In 2019, 34 countries had negative natural rates of increase; in 17 of these, the population
declined because immigration was not sufficient to counteract the negative rate of decline. Globally, HALE increased
from 58·6 years (56·1–60·8) in 2000 to 63·5 years (60·8–66·1) in 2019. HALE increased in 202 of 204 countries and
territories between 2000 and 2019.
Interpretation Over the past 20 years, fertility rates have been dropping steadily and life expectancy has been increasing,
with few exceptions. Much of this change follows historical patterns linking social and economic determinants, such
as those captured by the GBD Socio-demographic Index, with demographic outcomes. More recently, several countries
have experienced a combination of low fertility and stagnating improvement in mortality rates, pushing more
populations into the late stages of the demographic transition. Tracking demographic change and the emergence of
new patterns will be essential for global health monitorin
Health trends, inequalities and opportunities in South Africa's provinces, 1990-2019: findings from the Global Burden of Disease 2019 Study
Background Over the last 30 years, South Africa has experienced four ‘colliding epidemics’ of HIV and tuberculosis, chronic illness and mental health, injury and violence, and maternal, neonatal, and child mortality, which have had substantial effects on health and well-being. Using data from the 2019 Global Burden of Diseases, Injuries and Risk Factors Study (GBD 2019), we evaluated national and provincial health trends and progress towards important Sustainable Development Goal targets from 1990 to 2019.
Methods We analysed GBD 2019 estimates of mortality, non-fatal health loss, summary health measures and risk factor burden, comparing trends over 1990–2007 and 2007–2019. Additionally, we decomposed changes in life expectancy by cause of death and assessed healthcare system performance.
Results Across the nine provinces, inequalities in mortality and life expectancy increased over 1990–2007, largely due to differences in HIV/AIDS, then decreased over 2007–2019. Demographic change and increases in non-communicable diseases nearly doubled the number of years lived with disability between 1990 and 2019. From 1990 to 2019, risk factor burdens generally shifted from communicable and nutritional disease risks to non-communicable disease and injury risks; unsafe sex remained the top risk factor. Despite widespread improvements in healthcare system performance, the greatest gains were generally in economically advantaged provinces.
Conclusions Reductions in HIV/AIDS and related conditions have led to improved health since 2007, though most provinces still lag in key areas. To achieve health targets, provincial governments should enhance health investments and exchange of knowledge, resources and best practices alongside populations that have been left behind, especially following the COVID-19 pandemic
Health trends, inequalities and opportunities in South Africa's provinces, 1990-2019: findings from the Global Burden of Disease 2019 Study.
BACKGROUND: Over the last 30 years, South Africa has experienced four 'colliding epidemics' of HIV and tuberculosis, chronic illness and mental health, injury and violence, and maternal, neonatal, and child mortality, which have had substantial effects on health and well-being. Using data from the 2019 Global Burden of Diseases, Injuries and Risk Factors Study (GBD 2019), we evaluated national and provincial health trends and progress towards important Sustainable Development Goal targets from 1990 to 2019. METHODS: We analysed GBD 2019 estimates of mortality, non-fatal health loss, summary health measures and risk factor burden, comparing trends over 1990-2007 and 2007-2019. Additionally, we decomposed changes in life expectancy by cause of death and assessed healthcare system performance. RESULTS: Across the nine provinces, inequalities in mortality and life expectancy increased over 1990-2007, largely due to differences in HIV/AIDS, then decreased over 2007-2019. Demographic change and increases in non-communicable diseases nearly doubled the number of years lived with disability between 1990 and 2019. From 1990 to 2019, risk factor burdens generally shifted from communicable and nutritional disease risks to non-communicable disease and injury risks; unsafe sex remained the top risk factor. Despite widespread improvements in healthcare system performance, the greatest gains were generally in economically advantaged provinces. CONCLUSIONS: Reductions in HIV/AIDS and related conditions have led to improved health since 2007, though most provinces still lag in key areas. To achieve health targets, provincial governments should enhance health investments and exchange of knowledge, resources and best practices alongside populations that have been left behind, especially following the COVID-19 pandemic
Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2.5 air pollution, 1990-2019 : An analysis of data from the Global Burden of Disease Study 2019
Background
Experimental and epidemiological studies indicate an association between exposure to particulate matter (PM) air pollution and increased risk of type 2 diabetes. In view of the high and increasing prevalence of diabetes, we aimed to quantify the burden of type 2 diabetes attributable to PM2·5 originating from ambient and household air pollution.
Methods
We systematically compiled all relevant cohort and case-control studies assessing the effect of exposure to household and ambient fine particulate matter (PM2·5) air pollution on type 2 diabetes incidence and mortality. We derived an exposure–response curve from the extracted relative risk estimates using the MR-BRT (meta-regression—Bayesian, regularised, trimmed) tool. The estimated curve was linked to ambient and household PM2·5 exposures from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019, and estimates of the attributable burden (population attributable fractions and rates per 100 000 population of deaths and disability-adjusted life-years) for 204 countries from 1990 to 2019 were calculated. We also assessed the role of changes in exposure, population size, age, and type 2 diabetes incidence in the observed trend in PM2·5-attributable type 2 diabetes burden. All estimates are presented with 95% uncertainty intervals.
Findings
In 2019, approximately a fifth of the global burden of type 2 diabetes was attributable to PM2·5 exposure, with an estimated 3·78 (95% uncertainty interval 2·68–4·83) deaths per 100 000 population and 167 (117–223) disability-adjusted life-years (DALYs) per 100 000 population. Approximately 13·4% (9·49–17·5) of deaths and 13·6% (9·73–17·9) of DALYs due to type 2 diabetes were contributed by ambient PM2·5, and 6·50% (4·22–9·53) of deaths and 5·92% (3·81–8·64) of DALYs by household air pollution. High burdens, in terms of numbers as well as rates, were estimated in Asia, sub-Saharan Africa, and South America. Since 1990, the attributable burden has increased by 50%, driven largely by population growth and ageing. Globally, the impact of reductions in household air pollution was largely offset by increased ambient PM2·5.
Interpretation
Air pollution is a major risk factor for diabetes. We estimated that about a fifth of the global burden of type 2 diabetes is attributable PM2·5 pollution. Air pollution mitigation therefore might have an essential role in reducing the global disease burden resulting from type 2 diabetes
- …